The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Abstract Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomod...
Main Authors: | Martin Vališ, Anat Achiron, Hans Peter Hartung, Jan Mareš, Veronika Tichá, Pavel Štourač, Simona Halusková, Francesco Angelucci, Zbyšek Pavelek |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-08-01
|
Series: | Drugs in R&D |
Online Access: | https://doi.org/10.1007/s40268-023-00434-6 |
Similar Items
-
Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
by: Zbyšek Pavelek, et al.
Published: (2020-05-01) -
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01) -
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
by: Fatemeh Yavari, et al.
Published: (2021-03-01) -
Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
by: Gianmarco Abbadessa, et al.
Published: (2022-10-01) -
Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
by: Canan Duman İlki, et al.
Published: (2020-03-01)